Identification of Fusion Gene Breakpoints is Feasible and Facilitates Accurate Sensitive Minimal Residual Disease Monitoring on Genomic Level in Patients With PML-RARA, CBFB-MYH11, and RUNX1-RUNX1T1
2020
Abstrakt
In summary, our study shows that both the identification of genomic fusion sequences and the FG-based MRD monitoring are highly feasible in PML-RARA-/CBFB-MYH11-/RUNX1-RUNX1T1-positive AML. Quantification of FG, a stable target with a constant level per cell, enables precise assessment of the proportion of positive cells and represent a technically superior tool for the evaluation of therapy response than the so far widely used FT-based monitoring.
We believe that our data provides rationale for additional studies addressing the question whether such an improvement of evaluation of response to therapy could translate into an improvement of risk prediction and therapy tailoring - and, finally, of patients' outcome